| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b74452a889073845b47a40e23c273814 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D279-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D279-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D279-18 |
| filingDate |
2007-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9fa014ce2cbfba51fa1c25f31b68361
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f1ecd8b673aeb689a6a67541dacbc7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d5e1ba9cd30a64b465e9dc6bb7097c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b954a6ce82acb6b407d20a869b8a8fc6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e2b74bccd9bae8b49c14109c898141f |
| publicationDate |
2017-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2603783-T3 |
| titleOfInvention |
Synthesis and / or purification procedures for diaminophenothiazinium compounds |
| abstract |
Pharmaceutical composition which is a tablet or a capsule comprising from 20 to 300 mg of a high purity diaminophenothiazinium compound of the following formula: ** Formula ** in which: each of R1 and R9 is H; each of R3NA and R3NB is independently selected from: C1-4 alkyl; C2-4 alkenyl; and halogenated C1-4 alkyl; each of R7NA and R7NB is independently selected from: C1-4 alkyl; C2-4 alkenyl; and halogenated C1-4 alkyl; and X is one or more anionic counterions to achieve electrical neutrality; wherein the diaminophenothiazinium compound in the composition is characterized by: a purity greater than 98%; less than 1% of Azur B as impurity; less than 0.15% of Azur A as impurity; less than 0.15% Azur C as impurity; and less than 0.05% of MVB as impurity based said impurities on the weight of the diaminophenothiazinium compound in the composition, the composition further comprising a pharmaceutically acceptable carrier, diluent or excipient. |
| priorityDate |
2006-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |